

2024

# Annual Report

European Hematology Association

# Contents

European Hematology Association .....	1
Foreword from the President.....	5
1. About EHA.....	7
1.1. Executive Board.....	7
Committees, Subcommittees and other bodies .....	8
1.2. Fixed Committees.....	8
1.3. Committees .....	8
1.4. Subcommittees .....	9
1.5. 1.5 Other .....	9
1.6. Commitment to DEI at EHA.....	11
2. Membership.....	12
2.1. Our Members.....	12
2.2. Young EHA .....	14
2.3. EBAH.....	14
2.4. What members found important in 2024:.....	16
3. Connect & Network .....	17
3.1. Congress.....	17
3.2. Meetings & events .....	18
3.2.1. Scientific Meetings .....	18
3.2.2. Educational Meetings.....	19
4. Clinical Practice .....	21
4.1. Guidelines .....	21
5. Education & Training .....	23
5.1. EHA Campus.....	23
5.2. Learning paths.....	24
5.2.1. Curriculum.....	24
5.2.2. Lighting the Flame.....	24
5.2.3. Master Class .....	24
5.2.4. Preceptorships .....	25
5.3. Tests & Tools.....	25
5.3.1. EHA Exam .....	25
5.3.2. EHA Diagnosis .....	25
5.3.3. Mentoring & Career Development .....	25
5.3.4. Research Trainings .....	26

6.	Research & Innovation .....	27
6.1.	Grants & Funding .....	27
6.1.1	Our Impact .....	27
6.1.2	Bilateral Collaborative Grants (€320,000 for two years).....	27
6.1.3	Kick-Off Grants (€50,000 for one year) .....	27
6.1.4	Innovation Grants (€300,000 for two years).....	27
6.1.5	Research Mobility Grants (up to €10,000 for 3 months) .....	28
6.2.	HemaSphere.....	28
6.2.1	HemaSphere 2024 in numbers: .....	28
6.3.	Specialized Working Groups .....	29
7.	European Policy & Advocacy:.....	30
8.	Future Initiatives & Outlook.....	32
8.1.	Restructured Scientific Congress Program.....	32
8.2.	Digital Transformation.....	32
8.3.	Renewed Approach to Awards.....	32
8.4.	Mentorship Program .....	33
8.5.	Guidelines .....	33
8.6.	New Topics-in-Focus Preceptorship .....	33
8.7.	Advocacy Initiatives.....	33
9.	Acknowledgements.....	34
9.1	Sponsors & Supporters .....	34
9.2	Scientific Networks & Collaborations:.....	36
9.3	National Societies:.....	37
9.4	Sibling Societies:.....	38
10.	Operations & Financials .....	38
	Balance sheet as at December 31, 2024.....	38
	Statement of income and expenses for the year 2024 (in €) .....	39
	Notes to the financial statements.....	40
	Notes to the balance sheet as at December 31, 2024 (in €) .....	43
	Notes to the statement of income.....	47
	Notes to the statement of expense .....	49
	Budget 2025 .....	51
	Investing in the Future .....	52



# Foreword from the President

Borderless Hematology.

This phrase encapsulates what EHA is striving to achieve: enabling the best possible care for patients with hematological diseases by supporting the healthcare professionals and researchers working in the field of hematology. Complemented by our mission, “Towards prevention, cure, and quality of life for all patients with blood disorders”, we cover all aspects of hematology so that all our stakeholders can advance in their endeavor to ultimately serve the patient.

## **Strong growth**

As a member-focused association, we facilitate and promote close interaction between those working in the field of hematology. Over the past year, our membership has increased 17% with members from over 150 countries, an important indicator of how much our global community values our support. EHA nurtures the growth of the global hematology network through meetings, Specialized Working Groups (SWGs), a comprehensive educational offering and its new Community platform, My EHA. Our ambition is to connect hematologists worldwide to promote the exchange of knowledge and increase the quality of hematology care and research globally.

This is most visible in our flagship event: the EHA Congress. EHA2024 in Madrid had a record number of participants and presented abstracts. This year we have reformulated the congress program to provide space for even more original scientific results to be presented and to give greater opportunities for networking and collaboration.

## **Knowledge leaders**

Another important tool for dissemination of knowledge is our journal HemaSphere. Over the past year it has gone from strength to strength, achieving a 2023 impact factor of 11.9, the 7th most cited hematology journal worldwide. Our continuous investment in publication will facilitate more of our members to share their groundbreaking research.

Our educational portfolio is increasing progressively both in number and in the innovative formats through which content is delivered. The popularity of our microlearning activities and completion of courses on the EHA Campus, alongside the increasing recognition of the European Hematology Exam, is evidence of the valuable contribution EHA makes to harmonizing hematology education. We want to ensure that all hematologists have access to high quality education, are able to progress in their careers, enhance professional mobility, and grow competencies.

## **Innovative research**

EHA's investment in research has also increased substantially. More researchers are awarded grants each year and we promote collaboration and knowledge exchange through grants for consortia projects and exchange fellowships. Through our grant program, we aim to encourage those who already do excellent research; and to promote the implementation of research in regions that are underfunded, striving to improve the quality and access to research everywhere.

## **Stronger together**

To ensure our members derive the maximum benefit from EHA's activities, we work with national and European authorities to achieve the recognition of hematology as a specialty in all European countries. This recognition will facilitate career development and mobility of professionals, improving the standards of hematology everywhere.

By creating a strong hematology community, we are confident we will advance hematology and promote the best conditions for patient care. Our new corporate image and approach aim to ensure we include everyone and value all the remarkable activities and developments occurring in the world of hematology. Join us and benefit from the significant advantages and opportunities that belonging to EHA and its community provides. Together we can shape the future of hematology.

**António Almeida**

**President, EHA**

# 1. About EHA

EHA is dedicated to the prevention, cure, and better quality of life for all patients with blood disorders. We work to unite hematology professionals worldwide; by combining expertise, facilitating cooperation in research, and enabling accessible education, we ensure that knowledge is shared, and our community is empowered to make the best decisions.

In 2024, EHA embraced the concept of “Borderless Hematology” - a strategy designed to position us as the leading force in hematology. We believe progress in hematology comes from the strength of a united community that transcends physical and intellectual borders. When we come together - as researchers, clinicians, and advocates - we are more than dedicated individuals; we are a powerful force for the advancement of science and patient care.

## 1.1. Executive Board

The EHA Board is the association’s governing body and deals with policy issues. The Board sets the association’s goals and objectives in conformity with EHA’s statutes.

In addition to work planning and budgeting, the Board played a pivotal role in 2024 by participating in the organization’s shifting visual identity, defining core values, and setting strategic priorities.

The EHA Board is composed of six Executive Board members and ten councilors.

**Prof António Almeida**

President  
Hospital da Luz, Lisboa  
Portugal

**Prof Elizabeth Macintyre**

Past President  
Hôpital Necker-Enfants Malades et Université Paris Cité  
France

**Prof Konstanze Döhner**

President Elect  
Ulm University  
Germany

**Prof Martin Dreyling**

Treasurer  
University Hospital/LMU Munich  
Germany

**Prof Brian Huntly**

General Member  
University of Cambridge  
United Kingdom

**Prof Kristen Grønbæk**

Secretary

University of Copenhagen  
Denmark

In 2024, the Board Councilors were Prof Meritxell Alberich Jorda, Prof Maria Chiara Bonini, Prof Dominique Bonnet, Prof Jean-Pierre Bourquin, Prof Raul Cordoba, Prof Lucia De Franceschi, Prof Margarita Guenova, Prof Frank Leebeek, Prof Jose Maria Ribera, and Prof Evangelos Terpos.

Find out more about the EHA Board [here](#).

## **Committees, Subcommittees and other bodies**

EHA is composed of 19 active Committees and units set up by the Board to perform specific tasks and activities:

### **1.2. Fixed Committees**

#### **Good Governance Committee (GGC)**

The GGC is responsible for guarding EHA's image, position, and performance as a non-profit membership organization for public benefit, according to international standards and procedures on good governance.

#### **Nomination Committee (NC)**

The NC ensures the quality of the EHA Board is maintained by considering scientific and educational backgrounds, and by balancing competencies, fields of interest, geography and gender. The NC is also responsible for the nomination and ballot of EHA's Education & Mentoring Awards.

### **1.3. Committees**

#### **Community and Stakeholder Committee**

The CSC promotes the value of EHA and membership by providing guidance on membership strategies, engaging EHA members, building online communities, and collaborating with National Societies and Sibling Societies. They aim to share knowledge with hematology communities in less-resourced countries and create new opportunities for all stakeholders.

#### **Education Committee (EC)**

The EC promotes excellence in hematology education through high-quality, online learning programs, live meetings, and blended methods. Harmonizing hematology education drives all EC programs, activities, and actions.

#### **European Affairs Committee**

The European Affairs Committee represents and promotes the interests of hematology and hematologists by engaging with EU institutions and other relevant stakeholders.

#### **Research Committee (RC)**

The RC is responsible for further strengthening EHA's interactions with, and relevance for, the wider hematology research community by improving existing activities and developing new initiatives.



## **1.4. Subcommittees**

### **Curriculum-Exam Committee**

The Curriculum-Exam Committee aims to promote harmonization in hematology training by offering tools and programs that support this, such as the European Hematology Curriculum and the European Hematology Exam.

### **European Board for Accreditation in Hematology (EBAH)**

EBAH promotes harmonized high-quality Continuing Medical Education (CME) to provide the highest possible standard of patient and public healthcare within Europe. It aims to be the reference accreditation board in Europe for unbiased and transparent CME in hematology.

### **Fellowships and Grants Committee (F&GC)**

The F&GC is responsible for assigning EHA funding to talented researchers.

### **Guidelines Committee (GC)**

The GC's aim is to promote and support the creation and adoption of guidelines for diagnosing and treating hematologic diseases, in close collaboration with EHA Specialized Working Groups.

### **Patient Advocacy Committee (PAC)**

The PAC brings European umbrella patient organizations in hematology together to ensure patient voices are heard in EHA. The establishment of this Committee reflects the importance of facilitating an ongoing, mutually beneficial dialogue between hematology professionals and patients.

### **Specialized Working Group Committee**

The SWG Committee is the coordinating body of the EHA Specialized Working Groups, which aims to strengthen collaboration between the different SWGs and between EHA and the SWGs. Its members are selected within the SWGs and by the SWG Committee.

### **EHA-ASH TRTH Joint Oversight Committee**

The EHA-ASH TRTH Joint Oversight Committee aims to support translational researchers in their career development through the EHA-ASH Translational Research Training in Hematology (TRTH).

### **Young EHA Committee**

Young EHA represents the voice of young hematologists and junior members within EHA.

## **1.5. Other**

### **Clinical Case Unit**

The Clinical Case Unit guards the quality and consistency of all cases presented at EHA Tutorials and available on the EHA Campus.

### **Clinical Research Training in Hematology – Course Directors**

The CRTH course directors serve as an advisory committee to the EHA Research Committee and work closely with the EHA Office and other EHA Committees.

### **Computational Biology Training in Hematology (CBTH) Joint Oversight Committee**

The CBTH Joint Oversight Committee oversees the long-term development of the EHA-EMBL-EBI CBTH program, including program review, topic and faculty suggestion, and selection of scholars.

### **Diversity, Equity and Inclusion Task Force**

The Diversity, Equity, and Inclusion (DEI) Taskforce's mission is to initiate and implement activities that empower underrepresented groups. It achieves this by advising the EHA Board and committees on how to better promote diversity and inclusion in all EHA activities.

### ***HemaSphere* Editorial Board**

The Editorial Board reviews and selects articles, promotes *HemaSphere*, represents the journal, and ensures its quality and growth, aiming to establish it as a reputable society journal for European hematology research and related scientific news.

### **Scientific Program Committee (SPC)**

The SPC is responsible for creating a scientific and educational EHA Congress program that stands out in its excellence and includes the latest insights in hematology research and clinical practice.

### **SPC Advisory Board**

The SPC Advisory Board supports the SPC by creating a scientific and educational EHA Congress program that stands out in its excellence, and includes the latest insights and findings in hematology research and clinical practice.

A full description of the goals and responsibilities of each committee and unit is available [here](#). Open calls were made for nominations for the Board, Committees, SWGs, and the EHA2025 awards.

The EHA Board and its Committees are supported by the Executive Office, located in The Hague, the Netherlands, where an international team of staff works in a dynamic, collaborative, and open environment, taking pride in serving the hematology community in Europe and beyond.

## **1.6. Commitment to DEI at EHA**

Diversity, Equity, and Inclusion was at the forefront of EHA activities in 2024. The DEI Taskforce looked actively at how to fill the gaps in the three identified focus areas – age, gender, and underrepresented countries and regions by encouraging participation of diverse and underrepresented groups across our various activities.


### **Highlights**

- The first DEI Award was introduced during our Annual Congress, EHA2024. The recipient was Natacha Bolaños on behalf of the Lymphoma Coalition for the help provided to patients during the Ukraine crisis.
- A DEI Training schedule was created for an EHA-wide rollout in 2025.
- Inclusion considerations were advocated across all activities in 2024 with respect to age, gender, and underrepresented countries.


## 2. Membership

EHA's membership represents a wide range of professionals working in the field of hematology. Expanding our membership ensures we retain a diverse, global network of experts and stakeholders so that EHA is empowered to stay at the forefront of hematology research, drive innovation, and foster collaborations that lead to tangible improvements within the field.


### 2.1. Our Members




Active members 2024 & 2023




Top 10 Member Countries 2024 & 2023



Countries with the Most Joint Members 2023 & 2024



Member Gender 2024



Members Ages 2024

## 2.2. Young EHA

Young EHA is a network of early-career hematologists and hematology specialists. They work to advance the goals of, and address key issues for, the early-career community. Young EHA represents over 40% of our membership. The Committee provides a platform for young clinicians, researchers, and associated professionals to present their work, exchange ideas, and engage with leading experts in the field.

### Highlights

- Organized the **Young EHA Research Meeting (YERM)** during the British Society for Haematology (BSH) Annual Congress. The YERM received over 80 registrations and 40 abstract submissions of which 12 were selected for an oral presentation.
- Supported the **Burnout Initiative** from the Young National Society Ambassadors Network and Young EHA to address burnout among hematology professionals, starting with a blogpost in 2023, leading to webinars and a large survey conducted in 2024 that attracted 1,843 responses. This will be followed up with a research paper.

## 2.3. EBAH

**European Board for Accreditation in Hematology (EBAH)** is a reference accreditation board in Europe for unbiased and transparent Continuing Medical Education in hematology. With EHA support, EBAH continues to develop and aims to update its own mission and vision to align with EHA priorities on further hematology development.

## Highlights

- In 2024, EBAH saw a **61% increase** in accredited educational activities, totaling **121** for 2024 compared to 75 activities in 2023. This growth reflects the rising recognition of EBAH's quality standards in hematology.
- There was an **18% rise** in EBAH accounts, with numbers jumping from **20,760** to **22,832**, indicating heightened interest and engagement in EBAH-accredited events.
- Eight providers, including UPTODATE (US) and the Medical Learning Institute signed contracts to maintain the high-quality of these events.
- EHA also introduced the EBAH Handbook, a detailed guide for the accreditation process, underscoring the importance of thorough preparation for EBAH's rigorous assessment.

## 2.4. What members found important in 2024:

The member and stakeholder survey in 2024 clearly indicated what our members valued the most

1. **The Community is very satisfied.** EHA was given an NPS score of 39, which is a fantastic result for any association. This score is a great indicator of how satisfied and loyal members are.
2. **High-Quality Education and Resources:** Members greatly value access to high-quality educational materials, updates, guidelines, and opportunities for professional development. They seek more organized, up-to-date, and practical content, including specialized courses and workshops on advanced topics like CAR-T cell therapy and gene therapy.
3. **Networking and Collaboration:** Members appreciate the networking opportunities provided by EHA, particularly through congresses and scientific meetings. They emphasize the importance of international collaboration and knowledge exchange for advancing research and improving patient care. Our members are still looking for enhanced networking platforms and more structured opportunities.
4. **Support for Research and Funding:** There is a strong call for increased support for research, including more funding opportunities, clearer guidance on grant applications, and faster review processes. Members need more resources when they are starting out in their careers and better access to research funding.
5. **Patient Care and Advocacy:** Improving patient care is a top priority for members. They stress the need for high-quality clinical practice guidelines, standardized frameworks, and advocacy for better access to hematology medications and treatments, especially in regions with limited resources.
6. **Inclusivity and Accessibility:** Members from low- and middle-income countries (LMICs) and early-career professionals are looking for more inclusive membership benefits, and improved access to educational and networking opportunities.



## 3. Connect & Network

### 3.1. Congress

Under the presidency of **Prof António Almeida** and the supervision of **Prof Brian Huntly, Chair of the EHA2024 Scientific Program Committee (SPC)**, the EHA2024 Congress held from June 13-16 in Madrid, Spain, showcased groundbreaking advancements in hematology and strengthened collaboration within the global hematology community.

The EHA2024 Congress not only provided a platform for presenting and discussing the latest scientific research but also inspired a spirit of collaboration and innovation. By bringing together a diverse community of healthcare professionals, researchers, and industry experts, the EHA Congress facilitates meaningful dialogues and partnerships aimed at advancing the field of hematology. The collective effort and the knowledge shared in this global network are instrumental in driving progress and improving patient care and outcomes in hematology.

#### Reach and Participation

- **Total Registrations:** 17,896
- **Onsite Visitors:** 14,208
- **Virtual Registrations:** 2,358
- **Countries Represented:** 150

This impressive turnout underscores the Congress's importance as a hub for hematology professionals worldwide, facilitating the exchange of knowledge and expertise.

#### Impact and Highlights

The Congress featured an extensive program, including:

- **Research Presentations:** Over 1,260 posters and numerous oral presentations detailing the latest research in hematology.
- **Educational Sessions:** A wide range of workshops, symposia, and training sessions aimed at enhancing professional skills and knowledge.
- **Exhibition Booths:** A showcase of cutting-edge products, services, technologies, and partnerships from leading companies and organizations.

## Key Trends and Themes

1. **Lymphoid Malignancies:** A focus on the latest research and treatments for diseases such as lymphoma and leukemia, with significant discussions on CAR T-cell therapy and gene therapy.
2. **Myeloid Malignancies:** Innovations in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting new therapeutic approaches and clinical trials.
3. **Treatment of Hematological Disorders:** Emphasis on personalized medicine and novel treatments for multiple myeloma and chronic lymphocytic leukemia (CLL).
4. **Gene Therapy and CAR T-Cell Therapy:** Debates on the accessibility and implementation of these advanced therapies for broader patient populations.
5. **Sustainability in Research:** Strategies for reducing waste and improving efficiency in scientific research practices.

### 3.2. Meetings & events

#### 3.2.1. Scientific Meetings

The EHA brings together top experts from all hematological disciplines in a range of meetings throughout the year.

#### 6<sup>th</sup> European CAR T-cell Meeting

The premier European event for basic, translational, and clinical research in CAR T-cell immunotherapy was co-hosted by EHA and EBMT on February 15-17, 2024, in Valencia, Spain. Chaired by Prof M Hudecek and Prof A Sureda, the meeting covered a wide range of topics, including deep science, as well as translational, clinical, and commercial developments in CAR T therapy. A special highlight was the presentation of first-ever reported clinical data.

#### Research Conference 2024

The second edition of the EHA Research Conference, held from March 18-21, 2024, in Borovets, Bulgaria, focused on molecular vulnerabilities and metabolism in hematological disorders. The meeting brought together researchers to discuss the latest advancements in understanding the genetic and metabolic factors driving hematologic diseases.

#### EHA-SfPM Precision Medicine Meeting: Bridging functional and genomic precision medicine

This jointly organized meeting was the first to unite both genomic and functional precision medicine, with the aim of delivering the key information researchers need to investigate how to better deliver on the promise of precision medicine to cancer patients. The meeting was part of the EHA Topics-in-Focus (TIF) program on Precision Hematology, whose goal is to develop and optimize a European regulatory framework for precision medicine, with a focus on predictive diagnostics. This was the first meeting that brought together researchers and clinicians across all cancer types to address the common challenges in liquid and solid tumor settings. This is important as there is a significant overlap in the challenges faced in implementing novel predictive diagnostics in hematological and solid tumor settings.

### **3.2.2. Educational Meetings**

#### **Hematology Tutorials**

Hematology Tutorials provide laboratory and clinical hematologists with an integrated diagnostic and clinical workup of hematological disorders. The programs take participants through diagnostic and clinical pathways via plenary lectures, interactively conducted clinical case study sessions, and self-assessment sessions.

#### **EHA-MSH Hematology Tutorial**

On April 17-18, 2024, EHA joined the Malaysian Society of Haematology (MSH) to organize the EHA-MSH Hematology Tutorial on Hodgkin Lymphoma, held in Kuala Lumpur, Malaysia. This educational meeting was part of the pre-Congress program, preceding MSH's Annual Scientific Congress.

The tutorial focused on improving the treatment, diagnosis, and public awareness of Hodgkin Lymphoma in Malaysia and its surrounding regions, where outcomes still lag behind internationally published data.

#### **EHA-TSH Hematology Tutorial**

In collaboration with the Turkish Society of Hematology (TSH), EHA organized the EHA-TSH Hematology Tutorial on T Cell Lymphomas, held in Ankara, Türkiye, on June 29-30, 2024. This tutorial was designed specifically for hematology fellows from Türkiye, providing an in-depth educational experience focused on T cell lymphomas.

The meeting covered a range of critical topics, including the new classification and epidemiology of T cell diseases, and various treatment approaches for specific lymphoma subtypes.

#### **EHA-KCS Hematology Tutorial**

EHA, in collaboration with the Kazakhstan Cancer Society (KCS), organized the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies, held in Almaty, Kazakhstan, on September 14-15, 2024. The tutorial aimed to enhance doctors' understanding of the diagnosis and treatment of refractory and resistant manifestations of lymphoproliferative diseases. Pathologists also had the opportunity to improve their ability to accurately identify skin lymphomas. The meeting provided a platform for practical case-based learning, allowing participants to test their knowledge through patient-based examples from the region.

#### **EHA-GBMTA-AHA Hematology Tutorial**

EHA, in collaboration with the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and the Armenian Hematology Association (AHA), organized the EHA-GBMTA-AHA Hematology Tutorial from October 18-20, 2024, in Tbilisi, Georgia. The event focused on new aspects in the diagnostic choices and treatment options for hematological malignancies, aiming to enhance participants' knowledge in this critical field.

The meeting featured a combination of lectures, interactive self-assessment cases, and real patient case-based presentations, offering attendees a comprehensive understanding of the latest advancements in the biology, diagnostics, and management of hematological cancers.

### **EHA-Balkan Hematology Day 2024**

On April 19, 2024, in collaboration with national societies from the Balkan region, EHA co-organized the 5<sup>th</sup> EHA-Balkan Hematology Day in Tirana, Albania. The event, held in conjunction with the Albanian Association of Hematology Congress, focused on the role of Bone Marrow Transplantation (BMT) in treating malignant hemopathy in 2024.

Key sessions included the role of BMT in acute myeloid leukemia, therapy for relapsed/refractory non-Hodgkin and Hodgkin lymphoma, as well as the use of autologous stem cell transplantation (ASCT) in managing multiple myeloma. Additionally, the program addressed the role of BMT in treating acute lymphoblastic leukemia.

## 4. Clinical Practice

### 4.1. Guidelines

Throughout 2024, the EHA Guidelines team continued to expand its portfolio, while maintaining excellent collaborations with partner societies such as ASH, BSH, EAHAD, and ESMO.

In 2024, EHA agreed to take over the ESMO portfolio of malignant hematology guidelines, many of which are currently outdated. We committed to continuing the development and update of these guidelines, filling an important gap in the clinical practice guidelines landscape for malignant hematology. Work on the first two EHA-only lymphoma guidelines started in 2024 and will be completed in the first half of 2025. Updates to a large portion of the remaining former ESMO portfolio will start in 2025. The EHA Guidelines Committee Chair Prof Martin Dreyling and the EHA SWGs have been instrumental in these efforts.

Similarly, the non-malignant clinical practice guidelines portfolio has been growing steadily, with three newly started guidelines projects in 2024 and more planned for 2025.

#### **EHA Clinical Practice Guidelines portfolio 2024 in numbers: 13 ongoing projects**

##### **7 newly started guidelines:**

- EHA-EMN Guideline on **multiple myeloma** (former ESMO)
- EHA Guideline on **myeloproliferative neoplasms in patients age 25 or less**
- EHA Guideline on the management of **aggressive large B-cell lymphomas**: first line and beyond (former ESMO)
- Recommendations for antenatal screening and prenatal diagnosis for **hemoglobinopathies (β-thalassemia/SCD)**
- Management of patients with **mycosis fungoides/Sézary syndrome** in advanced stages (EHA-EORTC-EBMT)
- Consensus-based recommendation for the **diagnosis of rare hemolytic anemia**
- **Selecting beta-thalassemia patients for gene therapy/gene editing**: a decision-making algorithm [Guidelines update] (EHA-EBMT)

##### **2 newly published guidelines:**

- **Human immunodeficiency virus-associated lymphomas**: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  - <https://onlinelibrary.wiley.com/doi/10.1002/hem3.150>
- **Primary central nervous system lymphoma**: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  - <https://onlinelibrary.wiley.com/doi/10.1002/hem3.89>

##### **2 guidelines submitted for publication:**

- **Chronic Neutropenia Guidelines** Treatment Recommendations - Part II (submitted for publication)
- EHA ESMO Guideline on **peripheral T-cell lymphoma** (submitted for publication)

**4 guidelines sessions at EHA congress 2024:**

- HIV lymphoma (EHA-ESMO Guideline)
- Primary CNS lymphoma (EHA-ESMO Guideline)
- Neutropenia (EHA-EUNET INNOCHRON)
- Antithrombotic treatment in patients with hemophilia (EHA-ISTH-EAHAD-ESO Guideline)

**Patient care resources**

The Patient Advocacy Committee (PAC) represents the wider network of patient advocates. EHA works closely with patient advocates as they play an active role in advancing goals for access, research, quality of life, and dissemination of communication in hematology. Their input is pivotal in shaping policies and influencing decisions regarding access and reimbursement.

**Highlights**

- PAC welcomed two new member organizations, representing Childhood Cancer and Fanconi Anemia.
- PAC set priorities in line with the EHA Strategic Roadmap, focusing on research, access, quality of life, and communication & dissemination.

## 5. Education & Training

EHA's educational offering continues to expand—both in scope and in the innovative formats we use to engage the hematology community. From microlearning and interactive courses on the EHA Campus to the growing recognition of the European Hematology Exam, our programs support the harmonization of hematology education across Europe and beyond. Our aim is to ensure that, at every stage of their career, hematologists have access to high-quality learning opportunities that strengthen clinical competencies, support professional growth, and foster mobility across borders.

### 5.1. EHA Campus

EHA Campus is our comprehensive online learning platform that offers a wide range of courses, clinical cases, podcasts, and microlearning activities designed to support continuous education and professional development in hematology. In 2024, EHA Campus had a total of 171 comprehensive courses and clinical cases (18 programs, 113 courses, 129 podcasts, 58 cases).

- 17 new comprehensive courses released in 2024
- Grand total of 7,003 courses taken in 2024, of which 3,127 were completed
- 35,742 logins in 2024
- 4.6/5 star rating
- 98% want to engage in similar courses
- 97% would recommend our courses to their colleagues
- 79% say they made a change in their clinical practice after taking our courses.

#### EHA Microlearnings:

- Grand total of 251 microlearning items (55 EHACases, 50 LMs, 89 podcasts and 57 ThinkingThursdays (TT))
- 109 released in 2024 (24 EHACases, 23 LM, 36 podcasts and 26 TTs)
- 26 TTs in 2024: TTs feature educational summaries and clinical decision-making algorithms. They showcase EHA guidelines, HemaSphere papers, EHA meetings, and EHA Campus courses.
- CasEscape (learning gamification)
  - Over 720 learners have taken our 4 CasEscapes, rating them with 4.8/5, with many learners expressing similar sentiment to “This was great! For a topic I am not that familiar with, I was able to keep up. My thirst for what happened next kept me engaged.” and “It was quite fun and more importantly, informative!”

## **EHA Unplugged Podcasts:**

- 36 podcasts released in 2024
- 14.4K downloads, with 44% of listeners on Apple Podcasts, 33% on Spotify, and the rest on other channels. On Spotify alone, we have 2,400 unique listeners and 1,239 subscribers.
- Broad topics covered under EHA Unplugged  
EHA Unplugged features leading hematology experts discussing cutting-edge topics such as precision medicine, immuno- and gene therapies, and AI applications in clinical practice, while also featuring the "Hematology Portraits" series, offering listeners a unique blend of scientific insights and personal career journeys that have shaped the field of hematology.
- EHA Unplugged has been added to EHA's YouTube channel, providing listeners with a new platform to access its content.

## **5.2. Learning paths**

### **5.2.1. Curriculum**

As an addendum to the adult hematology syllabus, EHA and the European Society for Pediatric Oncology (SIOPe) have developed a pediatric hematology syllabus.

### **5.2.2. Lighting the Flame**

Lighting the Flame is EHA's free training program for medical students, interns, and residents who have not yet chosen a specialty. It is designed to 'spark' interest in the next generation of hematologists.

In 2024, Lighting the Flame hosted 9 Webinars.

Statistics from Lighting the Flame:

- Campus Logins: 3,660 in 2024 compared to 3,492 in 2023
- Campus Course Takers: 220 in 2024 versus 229 in 2023
- Physical Retreat: 51 participants (26 repeats, 25 new) from across Europe; 12 mentors

Collaboration with national societies has made Lighting the Flame an even greater success. In 2024, the Estonian society brought their expertise to the program through the support of local hematologists.

### **5.2.3. Master Class**

EHA Master Class is a specialized educational preceptorship program that provides advanced training and education in specific areas of hematology. It is held entirely online and is open to hematologists anywhere in the world.

- 86 participants in 2023-2024 group.
- 22 mentors in 2023-2024 group
- 5 case writers in 2024
- 81% passed in 2024



- Stats comparing 2023 vs 2024

Due to an increased interest from pediatric hematologists in 2024, a separate masterclass will take place in 2025-2026 with dedicated pediatric cases and mentors.

#### **5.2.4. Preceptorships**

Sickle Cell Disease: From Research to Clinical Management was EHA's first preceptorship program under the EHA Topics-In-Focus program. The meeting brought together 27 participants from 17 countries representing various SCD landscapes in Paris in October 2024. The three-day program was led by Prof Mariane de Montalembert and Dr Slimane Allali.

This initiative aims to foster a global exchange of SCD patient care expertise, improving diagnosis and treatment skills worldwide. Participants will learn to deliver holistic, culturally sensitive care, while also advancing their professional development in pediatric hematology.

### **5.3. Tests & Tools**

#### **5.3.1. EHA Exam**

The European Hematology Exam aims to certify excellent knowledge according to the criteria and topics of the [European Hematology Curriculum](#).

In 2024, a total of 244 candidates took the exam. The Exam was conducted in 15 countries. Besides the congress, 14 other parallel sessions were held. We saw a slight decrease in the pass rate in 2024 compared to 2023, 73% and 92% respectively.

In 2025, the EHA Exam aims to expand its reach by partnering with more national hematology societies to organize local parallel sessions. The focus will be on enhancing the accessibility and quality of the exam, ensuring it remains a valuable tool for assessing hematology knowledge and skills.

#### **5.3.2. EHA Diagnosis**

Launched in October 2024, EHA Diagnosis' primary purpose is to serve as a diagnostic reference resource and educational aid for hematologists. The platform aims to enhance the knowledge of hematologists on the morphological features of hematological conditions and improve their diagnostic skills.

As matters stand, we offer resources for AML diagnosis. Each diagnosis includes detailed descriptions of clinical and morphological features, along with high-resolution microscopy images of blood and bone marrow, and other relevant reference results such as immunophenotype and cytogenetics.

#### **5.3.3. Mentoring & Career Development**

##### **EHA Mentorship Program**

Launched at the end of 2024, this is a career development-focused, one-on-one mentorship program for clinicians and researchers. Thirty-five mentors have been selected, and applications for mentees will open in 2025.

#### **5.3.4. Research Trainings**

##### **- Computational Biology Training in Hematology (CBTH)**

This program is organized with the European Molecular Biology Laboratory - European Bioinformatic Institute (EMBL-EBI). Eighteen scholars were selected in 2024 who attended two, four-day workshops (April 16-20 and October 1-5) and a Congress session. Scholars represented eight different countries, of which the top three were the Netherlands, UK, and Germany.

##### **- Clinical Research Training in Hematology (CRTH)**

Sixteen faculty and 19 scholars attended two four-day workshops (February 6-10 and September 3-7) and a Congress session. Scholars came from 11 countries, the top four being the UK, the Netherlands, and Italy/Germany. The program introduced a work/life balance roundtable and a discussion on the use of social media in supporting career development.

##### **- Translational Research Training in Hematology (TRTH)**

Organized with the American Society of Hematology (ASH), the Program had 19 faculty members, including a past trainee. There were 24 scholars, balanced between those from North America (12) and others – the top three countries being the UK, Germany and France. Attendees joined a week-long spring course (March 8-15), an EHA Congress session and an ASH Annual Meeting session.

#### **Highlights and Statistics from Researchfish Reporting**

Researchfish is an online platform that offers an annual survey for current and past grantees and research training scholars to measure the impact of our programs on career development and trajectory.

##### **CRTH: 91 scholars submitted survey responses in 2024:**

- € 24,145,751 further funding was secured thanks to CRTH participation
- 267 publications were reported, mostly within 3 years of CRTH attendance
- 50 new collaborations were reported, mostly with hospitals (38%)
- 11 clinical trials were reported

##### **TRTH: 242 scholars submitted survey responses in 2024:**

- € 267,812,856 further funding was secured thanks to TRTH participation
- 1,100 publications were reported, mostly within three years of TRTH attendance
- 84 new collaborations were reported, mostly with academic centers (63%)

## 6. Research & Innovation

EHA marked 2024 with a record investment (more than five million Euros) in activities in support of researchers in hematology. We have expanded our grants offer and look forward to continued development in hematology research.

### 6.1. Grants & Funding

#### 6.1.1 Our Impact

Researchfish is an online platform that offers an annual survey for current and past grantees and research training scholars to measure the impact of our programs on career development and trajectory. In 2024, 489 current and past awardees were asked to make a submission between 01 February – March 15, 2024.

Grants: 136 grantees submitted survey responses in 2024:

- €75,909,129 further funding was secured thanks to an EHA grant.
- 425 publications were reported, mostly within three years of starting the grant period.
- 89 new collaborations were reported, mostly with academic centers (52%) followed by hospitals (29%).

#### 6.1.2 Bilateral Collaborative Grants (€320,000 for two years)

This grant supports collaboration between two independent research groups located in two different European countries. In 2024, 3 grants were awarded to 6 grantees across 5 countries: Germany (2), Italy, Spain, Switzerland and United Kingdom.

#### 6.1.3 Kick-Off Grants (€50,000 for one year)

These grants support high-risk but potentially high-impact research ideas. In 2024, 11 grants were awarded across 9 countries: Austria, Belgium, France, Germany (2), Italy, Norway, Portugal, Spain (2) and Switzerland.

#### 6.1.4 Innovation Grants (€300,000 for two years)

Supports the creation of consortia and the generation of preliminary data to facilitate applying for larger funding. In 2024, 3 grants were awarded to 11 grantees across 7 countries: Croatia (2), Finland, France, Germany (3), Portugal, Sweden and United Kingdom (2).

EHA Research Grants (€150,000 for 3 years for Junior Research Grants; €240,000 for 3 years for Advanced Research Grants; €240,000 for 3 years for Physician Scientist Research Grants) Supports talented junior researchers in advancing their career. In 2024, 5 Junior Research Grants were awarded across 5 countries: Czech Republic, France, Iceland, Netherlands and Sweden. In 2024, 5 Advanced Research Grants were awarded across 4 countries: Italy, Netherlands (2), Spain and Sweden. In 2024, 4 Physician Scientist Research Grants were awarded across 4 countries: France,

Netherlands, Portugal and United Kingdom. In 2024, 1 grantee from Italy was awarded a Topic-in-Focus Advanced Research Grant.

#### **6.1.5 Research Mobility Grants (up to €10,000 for 3 months)**

Supports mobility and facilitates a visit to a research group in another institute. In 2024, 14 grants were awarded across 8 countries: Canada, Czech Republic (4), France, Italy (2), Netherlands, Spain (3), and Switzerland (2).

## **6.2. HemaSphere**

*HemaSphere* is EHA's official, peer-reviewed, open access journal publishing impactful research spanning basic, clinical, and translational hematology. 2024 was another successful year of growth for the journal, as the rate of submissions, overall publication citations, and journal benchmarking metrics continue to rise. This was the first year that *HemaSphere* earned an impact factor above 10 (11.9 to be exact), but also a seat in the top-10 hematology journals worldwide.

Following a successful 2023 pilot series, we recorded and released the second season of the *HemaSphere* Podcast in 2024. Engagement on EHA's social media account grew overall, and we further promoted the journal at several EHA events, including the EHA Research Conference 2024 and the EHA Annual Congress, where we launched *HemaSphere*'s first-ever awards program. In addition, 2024 was the journal's first full calendar year working with its new publisher, Wiley, which yielded fine-tuned systems and processes, new awareness campaigns via Wiley's marketing team, and relationship-building with other hematology journals.

### **6.2.1 HemaSphere 2024 in numbers:**

- Journal Impact Factor increased to 11.9
- Ranked #7 out of 97 hematology journals worldwide
- Scopus Annual CiteScore increased to 6.1
- 27% increase in manuscript submissions compared to 2023; 45% increase compared to 2022
- 155 publications in 2024
- 2024 journal acceptance rate: ~20%

### 6.3. Specialized Working Groups

**Specialized Working Groups (SWGs)** are groups of experts in various specialties, made up of EHA members, that aim to foster science and spread knowledge in basic, translational and clinical research in hematology. EHA has a network of 25 SWGs divided between disease areas (AML, MDS, others) and overarching topics such as quality of life, diagnostics, and others. SWGs provide a pipeline of experts who contribute to guidelines, research, speaker engagements, scientific meetings, and designing training and career advancement programs.

#### Highlights

- **SWG network membership** experienced significant growth in 2024, with membership nearly doubling to 1,100 members, an almost 50% increase compared to the previous year.
- **SWG Framework rollout** – The framework governing the functioning of the SWG network was rolled out for implementation in 2024.
- **EHA Congress 2024** in Madrid saw almost 8,500 attendees at SWG scientific sessions.
- **SWG Research Projects and Grants:** In 2024, the EHA Board funded five research grants of up to €30,000 each, covering topics like Infections in Hematology, Gaucher Disease, Lymphomas, Immunotherapy, and Systemic Leukemia in Children.
- **SWG Involvement in Other Programs:** Three EHA SWG Joint Symposia were organized in 2024, and the SWG on Pediatric Hematology collaborated with the Fondazione Matilde Tettamanti to develop the 11<sup>th</sup> EHA Pediatric Hemato-Oncology ("Sorrento") Course, which attracted 62 participants and received excellent feedback.
- **Launched the first Online Journal Club** and planned four SWG scientific meetings for autumn 2025-2026.

## 7. European Policy & Advocacy:

Throughout the year, EHA made its voice heard in discussions or during decision-making on EU health policies of importance to hematologists and their patients. Whenever possible, we made sure that our researchers and clinicians were at the table. In terms of frontline involvement in policy and regulatory processes, 2024 was a particularly successful year:

- 1 of 4** HCP organizations selected for the permanent ACT EU stakeholder advisory group  
→ *prominent voice in shaping EU regulatory framework for clinical trials*
- 1 of 4** medical societies invited to present to the Cancer Mission Board  
→ *increased visibility of EHA and hematology in the crowded EU cancer policy landscape*
- 1 of 3** leading medical societies on the EU HTA Stakeholder Network  
→ *leading role in shaping medical societies' involvement in joint HTA*
- 1 of 3** learned societies on the EMA Cancer Medicines Forum  
→ *leading academic partner in dialogue on evidence challenges*
- 1 of 1** HCP representative on the HMA/EMA Network Data Steering Group  
→ *hematologist selected to represent all Europe's HCPs in top regulatory body on (big) data*
- #1** Elizabeth Macintyre President of the BioMed Alliance  
→ *visibility & prestige for EHA and hematology, recognition of lead role in cross-disciplinary advocacy*

EHA's policy and regulatory work aims to improve access to innovative therapies for patients with hematologic diseases. We also advocate for increased funding and collaboration opportunities for hematology research, and for better, less bureaucratic and more patient-centered regulatory and governance frameworks.

We make a difference for our members by taking a holistic and collaborative approach. We engage with policymakers, regulators, health technology assessment (HTA) bodies and payers across the whole access decision-making chain. Since many of the challenges we face are not exclusive to hematology, we align and cooperate closely with other medical professions, patient organizations, and other stakeholders.

### Highlights:

The **BioMed Alliance** takes a prominent place in EHA's collaborative approach. Milestones included the launch of a new Health Research Committee and the first edition of a regulatory Training Day for researchers and clinicians involving leading European Commission and European Medicines Agency (EMA) officials. EHA also leads the BioMed Alliance HTA working group.

In November, EHA leaders were invited to present hematologists' views and priorities to the **Cancer Mission Board**. As a multistakeholder expert body, facilitated by the European Commission, it informs both the Horizon Europe Cancer Mission, the EU's funding program for research and innovation, and Europe's Beating Cancer Plan. EHA was only the fourth medical society to be invited since the Board's inception in 2021. The meeting with the Cancer Mission Board represented an

important step towards gaining more visibility and support for hematology in EU cancer policy-making.

**ACT EU** is the platform for collaboration between regulators and stakeholders on clinical trials governance in the EU. EHA, as a member of the permanent advisory group, has been instrumental in getting topics onto the ACT EU agenda that are of major importance to hematology, such as early advice for academic investigators, non-interventional trials, reducing bureaucracy, and support for clinical research in rare diseases and ATMPs.

EHA has been a leading stakeholder in shaping **EU HTA**. As a member of the formal HTA Stakeholder Network, EHA successfully advocated for early and effective involvement of clinicians and medical societies in implementing the HTA Regulation (from January 2025). An EHA-National Societies HTA network was created to facilitate alignment across expert networks and encourage interaction with HTA bodies at the national level.

In June, EHA hosted the **ASCERTAIN** consortium in Madrid, where some of its protagonists subsequently spoke during Congress sessions on unmet needs and pricing in the EHA-Patient Joint Symposium. The consortium brings together academic institutions, patient advocates, payers, HTA experts, Austria's public health institute, and EHA to develop new policy support tools for cost-effectiveness, pricing and reimbursement. The goal: better and more aligned access to decision-making across Europe.

At the end of the year, EHA's nominee Kimmo Porkka was selected as representative of Europe's healthcare professionals for the **Network Data Steering Group (NDSG)**. This multi-disciplinary expert group, established by EMA and the Heads of Medicines Agencies (HMA), will guide regulatory strategies on data interoperability, exchange and the use of data across the EU medicines regulatory network, evidence generation, and artificial intelligence.

## 8. Future Initiatives & Outlook

### 8.1. Restructured Scientific Congress Program

In 2025, EHA will celebrate the 30<sup>th</sup> anniversary of its Annual Congress. Throughout the last 30 years, we've created unforgettable experiences that foster connections, sparks innovation, and accelerate progress in hematology.

In 2025, we are transforming the EHA Congress experience by introducing even more opportunities for attendees to learn and connect. The full scientific program will run from Thursday to Sunday in 2025, meaning participants will have the opportunity to hear more clinical trial results, access more research data, and attend a greater number of sessions with scientific speakers and industry partners.

### 8.2. Digital Transformation

In 2025, EHA will launch the MyEHA Community Platform – a virtual hub enabling members to engage, network, and collaborate. The platform will serve as a central space for discussions, knowledge exchange, and information on how to get involved with EHA's huge range of opportunities.

To complement this, EHA will be launching a new website with an improved user experience, including an overhaul of the navigation system, visuals, and content. This means that our members will be able to better access the information they need to enhance their careers.

Finally, for those just beginning their hematology careers, EHA will be launching a career-mapping website, helping young students to identify the most appropriate paths to get the training they need depending on the country in which they are studying. We will provide insights into the hematology training opportunities that exist in 30+ European countries.

### 8.3. Renewed Approach to Awards

In 2025, we will renew our approach to celebrating breakthroughs in hematology and acknowledging successes within our global community. In doing so, we will now award participants in the following award categories:

- EHA Lifetime Achievement Award
- EHA Clinical Excellence Award
- EHA Research Excellence Award
- EHA Education and Mentoring Award
- EHA Diversity, Equity, and Inclusion Award
- Young EHA Award
- *HemaSphere* Top-Cited Paper – Basic Research
- *HemaSphere* Top-Cited Paper – Clinical Research



#### **8.4. Mentorship Program**

Our mentorship program is starting in 2025, offering individual mentoring support for early and mid-career clinicians and researchers in hematology. In doing so, EHA aims to give participants the opportunity to make the most of their career potential, accelerate progress and innovation in research and clinical practice, and facilitate effective communication and international collaboration.

#### **8.5. Guidelines**

Following a shift in strategy from the European Society of Medical Oncology (ESMO), EHA looks forward to taking the lead in generating hematology-focused clinical practice guidelines. With over 15 guidelines published, we look forward to sharing the latest diagnostic, care, and follow-up advice on lymphoma, neutropenias, and more.

#### **8.6. New Topics-in-Focus Preceptorship**

In 2025, EHA will launch a new Topics-in-Focus program on Precision Hematology with a focus on diagnostics. The goal of the program is to develop and optimize a European regulatory framework for precision hematology, with a focus on diagnostics and clinical research in malignant hematology.

#### **8.7. Advocacy Initiatives**

In 2025, we are looking forward to carrying out a stakeholder mapping project to better understand the hematology landscape across Europe. We will also continue working on our advocacy efforts in the context of the new EU Pharmaceutical Legislation, offering our perspective alongside fellow stakeholders on this crucial regulation.

## 9. Acknowledgements

EHA would like to thank the following partners for their support in 2024.

### 9.1 Sponsors & Supporters

#### Platinum sponsor

**Johnson & Johnson**

 Bristol Myers Squibb®

**abbvie**

 **NOVARTIS**

 **astellas**

**sanofi**

#### Gold sponsor

**AstraZeneca** 

**GSK**

 **BeOne**

 **Roche**

 **Pfizer**

 **Lilly**  
A MEDICINE COMPANY

 **Incyte**

**REGENERON**  
SCIENCE TO MEDICINE®

 **VERTEX**

 **GILEAD**

 **Kite**

 **Genmab**

#### Silver sponsor

 **Jazz Pharmaceuticals.**

 **Stemline®**  
A Menarini Group Company

 **Otsuka**

## Bronze sponsor



## Contributors



## **9.2 Scientific Networks & Collaborations:**

In 2024, EHA collaborated with the following Scientific Networks.

### **CarrerasLeaders:**

CarrerasLeaders is a postdoc fellowship and training program for the next generation of researchers. Coordinated by the Josep Carreras Leukaemia Research Institute, EHA supported promotion efforts in 2024 for the new call for 16 CarrerasLeaders post-doctorate research projects.

### **EuroBloodNet:**

Launched in early 2017, EuroBloodNet (European Reference Network for rare hematological diseases) was born from the joint efforts of EHA and the European Network for Rare Congenital Anemias (ENERCA) to bring together over 100 highly specialized hospital centers with expertise on rare malignant and non-malignant hematological diseases.

In 2024, we worked together to support various ERN webinar series, raising awareness of rare hematologic diseases. EHA also formally endorsed the RADeep registry for rare anemias that was conceived in the core of EuroBloodNet and invited leading ERN experts to join the EHA Hemoglobinopathies Taskforce.

### **INTERCEPT-MDS MSCA:**

EHA was a proud associated partner of the INTERCEPT-MDS Marie Skłodowska Curie Action (MSCA) Doctoral Network (DN). INTERCEPT-MDS concluded at the end of 2024.

### **Health Technology Assessment (HTA):**

As a member of the HTA Stakeholder Network, EHA played an active role in preparations for the implementation of the EU HTA Regulation (from January 2025). Throughout the year, EHA was a leading voice for effective involvement of clinical experts and medical societies in the joint clinical assessments (JCA). High-quality, evidence-based JCA are expected to help improve and harmonize decision making on access at the national level.

### **T2EVOLVE:**

T2EVOLVE is a breakthrough alliance working to accelerate development and increase access to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). T2EVOLVE, the IMI European project dedicated to CART, completed its fourth year in 2024, meeting all the objectives, publications and meetings planned. EHA has supported T2EVOLVE with Project Management of specific tasks and hosting network meetings at the EHA-EBMT CAR-T meeting and at the EHA Congress.

### **HARMONY Alliance:**

EHA has been proud to participate in the IHI calls for HARMONY and HARMONY PLUS (European Public-Private Partnership for Big Data in Hematology) for over eight years. This close collaboration achieved significant success, providing new insights that will undoubtedly contribute to advances in novel therapies and more effective medicines. The projects concluded at the end of 2024.

We extend our deepest thanks to the entire HARMONY team for their remarkable work in advancing the use of big data and analytics in hematology for nearly a decade and wish them well for their future endeavors.

#### **Ongoing MSCA doctoral networks: FANTOM, Inno-CART, TOLERATE**

FANTOM comprises of 7 beneficiaries and 12 associated partners in 5 EU countries, recruiting 10 researchers and is embedded into an established international research program: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) and a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL).

InnoCAR-T is a MSCA-DN designed to provide training and carry out breakthrough research on the rapidly expanding and high-impact field of Chimeric Antigen Receptor (CAR) T cell immunotherapy in a carefully integrated academic and inter-sectoral program.

TOLERATE is an interdisciplinary and intersectoral MSCA- DN focused on developing innovative antigen-specific immune therapies for autoimmune diseases. It builds on the experiences of the PROFILE Innovative Training Network (ITN).

EHA has supported FANTOM, Inno-CART, and TOLERATE as an associate partner, disseminating calls and information about the network, hosting trainees and offering the projects the opportunity to raise awareness of their aims at the EHA2024 Annual Congress and other EHA meetings.

#### **GoCART:**

The GoCART Coalition is a multi-stakeholder coalition collaborating to maximize the potential of cellular therapies manufactured from cells and tissues of hematopoietic origin. The coalition was co-founded by EHA and EBMT, and EHA has the lead on website and media. In 2024 GoCART has kept growing with new identified needs converted into projects, such as the CART Passport and Observership program.

### **9.3 National Societies:**

National hematology societies represent the local community of hematologists. EHA closely collaborates with national societies to ensure the professional hematology community in Europe is served in the best way possible, reinforcing each other's actions on the European and national levels.

#### **Highlights:**

- The National Society Days 2024 saw participation from more than 26 national societies.
- EHA organized joint symposia with 17 countries, fostering knowledge-sharing and advancing hematology worldwide.
- Collaboration with Nigerian Society for Haematology and Blood Transfusion, with a successful webinar on Sickle Cell Disease. This webinar attracted over 300 registrations and was attended by 130 unique users.
- **Young National Society Ambassadors (YNSA):** Representing the early career community, YNSA contributed to the career-mapping initiative by sharing hematology education trajectories from

their respective countries. This initiative aims to enhance talent mobility, deepen understanding of career paths, and harmonize education and training across different countries.

- **New joint memberships:** EHA has taken significant steps to strengthen its membership network by establishing joint memberships with France and Hungary in 2024, facilitating better engagement and integration of hematologists within the European and global hematology communities.
- **EHA-National Societies HTA network:** To facilitate information sharing, active involvement of hematologists and consensus-building across European and national networks, 2024 saw the creation of a network for collaboration on HTA.

#### 9.4 Sibling Societies:

**Sibling Societies** are peer associations in hematology, hemato-oncology, and related disease areas. EHA collaborates with sibling societies to reach a wider audience, expand its network of professional contacts, and strengthen its reputation as a leading organization in hematology.

#### Highlights:

- Joint symposia with the European Society for Blood and Marrow Transplantation (EBMT) and the International Society of Blood Transfusion (ISBT).
- A joint meeting with the European School of Haematology in 2024.

## 10. Operations & Financials

EHA is a common good non-profit organization under Dutch law. It receives its funding through corporate partnerships with industry partners and through activity-based sponsorships for EHA's programs.

Profits generated from its Congress and other programs are invested in activities that serve the hematology community, according to the objectives and mission of EHA. EHA operates as a Board-led organization, with the Executive Board and its Committee members contributing voluntarily for a specified term. The EHA Executive Office spearheads the implementation of the organization's strategy, supported by a team of highly experienced professionals.

#### Balance sheet as at December 31, 2024

Assets		31-12-2024	31-12-2023
Fixed assets			
	Intangible fixed assets	151.608	97.780

	Tangible fixed assets	640.891	269.110
<b>Current assets</b>			
	Trade debtors	1.014.714	2.872.407
	Taxes and social security charges	97.737	177.826
	Receivables, prepayments and accrued income	2.325.031	1.085.434
<b>Cash and equivalents</b>		30.090.055	31.333.937
		34.320.036	35.836.494

<b>Equity &amp; Liabilities</b>		<b>31-12-2024</b>	<b>31-12-2023</b>
<b>Equity</b>			
	Other reserves	22.819.576	27.211.175
	EHA Fund	1.000.000	1.500.000
<b>Long term liabilities</b>			
	Long term Liabilities Grants	5.359.543	1.483.324
<b>Current liabilities</b>			
	Short term Liabilities Grant	487.246	1.974.155
	Trade creditors	1.562.409	652.260
	Taxes and social security	116.352	114.470
	Other liabilities, accruals and deferred income	2.974.910	2.901.110
		34.320.036	35.836.494

### Statement of income and expenses for the year 2024 (in €)

<b>Income</b>	<b>Actual 2024</b>	<b>Budget 2024</b>	<b>Actual 2023</b>
Connect	19.601.822	16.839.800	17.691.856
Public Relations	3.524.714	4.000.000	4.239.291
Community (engagement)	794.342	709.000	600.642
Research	513.799	190.000	568.009
Education	416.684	765.000	446.527
Scientific Publications	85.000	465.000	-
miscellaneous		7.100	
<b>Total</b>	<b>24.936.362</b>	<b>22.975.900</b>	<b>23.546.325</b>

<b>Expenses</b>	<b>Actual 2024</b>	<b>Budget 2024</b>	<b>Actual 2023</b>
Connect	10.708.335	10.035.000	10.361.136
Research	7.092.604	5.621.000	3.998.254
Operations	3.780.408	2.994.000	3.092.363
Education	1.973.324	2.024.000	1.099.322

Community (engagement)	2.999.911	2.770.000	957.570
Public Relations	1.711.972	1.530.000	392.540
Scientific Publications	880.331	1.311.000	334.365
European Affairs	901.630	866.000	517.182
Good Governance	37.338	30.000	
Works Council	8.949	20.000	
<b>Total</b>	<b>30.094.802</b>	<b>27.201.000</b>	<b>20.752.732</b>

<b>Result before financial income and expenses</b>	<b>(5.158.439)</b>	<b>(4.225.100)</b>	<b>2.793.593</b>
Financial income and expenses	266.841	75.000	4.031
Reservation Special purpose Reserve			(1.500.000)
Withdrawal from special Purpose Reserve	500.000		
<b>Net Result</b>	<b>(4.391.598)</b>	<b>(4.150.100)</b>	<b>1.297.623</b>

The special purpose reserve concerns an investment by EHA in the EHA Foundation. The Foundation has been founded in 2024 and a first tranche of 500k has been paid out. During the course of 2025 the foundation will acquire the ANBI status.

## Notes to the financial statements

### General

The legal form of the organization is an association.

The actual office address is Koninginnegracht 12b in The Hague.

### Identification data of the company

Name	European Hematology Association
Registered office	The Hague
Chamber of Commerce number	24334797

### Staff

During the 2024 financial year, on average 48.7 employees (in FTE) were employed (2023: 42).

### Comparative figures

The valuation principles and method of determining the result are the same as those used in the previous year.

### Mission Statement

The European Hematology Association promotes excellence in patient care, research and education in hematology.



### **General accounting principles for the preparation of the annual accounts**

The financial statements are prepared in accordance with the Guideline for annual reporting 640 'Not-for-profit organizations' of the Dutch Accounting Standards Board.

The financial statements are prepared in euro, the functional currency of the European Hematology Association.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are carried at nominal value.

Income and expenses are accounted for on accrual basis. Profit is only included when realized on the balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

Revenues from goods are recognized upon delivery. The cost price of these goods is allocated to the same period. Revenues from services are recognized in proportion to the services rendered. The cost price of these services is allocated in the same period.

Transactions in foreign currencies are recorded at the FX-rates of the dates of the transactions. At the end of the financial year the unsettled balances of foreign currency transactions are revalued at the year-end FX-rates.

### **Principles of valuation of assets and liabilities**

#### **- Intangible fixed assets**

Intangible fixed assets are presented at acquisition price less cumulative depreciation and, if applicable, less impairments in value. Depreciation is based on the estimated useful life and calculated as a fixed percentage of cost, taking into account any residual value. Depreciation is provided from the date an asset comes into use.

Please note: EHA no longer holds intangible fixed assets. Our current position is to put investments in websites and other immaterial assets directly into our profit and loss account.

#### **- Tangible fixed assets**

Tangible fixed assets are presented at acquisition price less cumulative depreciation and, if applicable, less impairments in value. Depreciation is based on the estimated useful life and calculated as a fixed percentage of cost, taking into account any residual value. Depreciation is provided from the date an asset comes into use.

#### **- Depreciation rates**

<b>Asset</b>	
Intangible assets: consisting of website EHA	33%
Office inventory: consisting of immoveable items	10%
Office equipment: consisting of immovable items	20%
Land and buildings	10%

The "Land and Buildings" category currently holds no value, and no further investments will be allocated to it.

- **Receivables and deferred assets**

Receivables are initially valued at the fair value of the consideration to be received, including transaction costs if material. Receivables are subsequently valued at the amortized cost price. Provisions for bad debts are deducted from the carrying amount of the receivable.

- **Cash and cash equivalents**

Cash and cash equivalents are valued at nominal value. Cash and cash equivalents consist of credit balances on bank accounts, cash in transit and cheques and demand deposits.

- **Current liabilities**

On initial recognition current liabilities are recognized at fair value. After initial recognition current liabilities are recognized at the amortized cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

### **Principles for the determination of the result**

- **General**

The result is determined based upon the difference between the net turnover and the costs and other expenses taking into account the aforementioned valuation principles.

- **Revenue**

The income represents amounts invoiced for registration fees, sponsorships and services supplied during the financial year reported on, excluding Value Added Taxes.

- **Pension charges**

European Hematology Association has a pension scheme on which the provisions of the Dutch Pension Act are applicable. European Hematology Association pays premiums based on a contractual obligation to an insurance company. Premiums are recognized as employee costs when they are due. Prepaid contributions are recognized as deferred assets, if these lead to a refund or reduction of future payments. Contributions that are due but have not yet been paid are presented as liabilities. European Hematology Association has no obligations for any deficit of the insurance company, other than payment of increased future premiums.

- **Amortization and depreciation**

The depreciation on tangible fixed assets is calculated by using a fixed rate on the acquisition cost. Gains and losses on disposal of tangible fixed assets are recorded under depreciation.

- **Financial income and expenses**

Interest income and expenses concern interest income and expenses on bank balances and related costs.

## Notes to the balance sheet as at December 31, 2024 (in €)

Intangible fixed assets	Website
Acquisitions prior to 1-1-2024:	118.890
Accumulated depreciation and impairment	(21.110)
Book value balance 1-1-2024	97.780
Movement during the year 2024	
Investment	119.015
Depreciations	(65.187)
Balance per 31-12-2024	
Acquisitions:	237.905
Disinvestment	
Accumulated depreciation and impairment	(86.297)
Closing balance	<b>151.608</b>

Mid of 2025 EHA will launch a new website. Therefore the current website has been increased in depreciation rate. The investments in the new website are 119k and will be depreciated yearly with 33%.

Tangible fixed assets	Land & Building	Office inventory	Office equipment	Total
<b>Acquisitions:</b>	385.235	118.211	295.199	798.645
Accumulated depreciation and impairment	(307.381)	(62.214)	(159.940)	(529.535)
Book value opening balance	77.854	55.997	135.259	269.110
<b>Movement during the year</b>				
Investment	(0)	490.260	16.322	506.581
Depreciations	(77.854)	(22.620)	(34.327)	(134.801)
Total of changes	(77.854)	467.640	(18.005)	371.781
<b>Balance per 31-12-2024</b>				
Acquisitions:	385.235	608.471	311.521	1.305.227
Accumulated depreciation and impairment	(385.235)	(84.834)	(194.267)	(664.336)
Closing balance	<b>(0)</b>	<b>523.637</b>	<b>117.254</b>	<b>640.891</b>

In 2024 the EHA office was revamped. This caused 490k investment under "Office Inventory". EHA strives for a modern and sustainable office, and the revamp was deemed necessary for this purpose. EHA has also faster depreciated other fixed assets, to supports this endeavour by allowing for more frequent replacement, which will contribute to both appearance and durability.

## Specification of currents assets

Debtors	2024	2023
Trade debtors	1.081.214	2.870.907
Provision for doubtful debtors	(66.500)	(1.500)
<b>Total Debtors</b>	<b>1.014.714</b>	<b>2.872.407</b>

The decrease in EHA debtor account from €2.8 mln in 2023 to €1.1 mln in 2024, is due to our invoicing practice. In 2023, invoices for congress 2024 were issued but remained largely unpaid, leading to a higher debtor balance. In 2024, the congress invoices for 2025 were sent out and paid out earlier by our sponsors.

A provision for doubtful debtors has been created on the basis of 2 invoices which have an overdue of more than 1 year and administrative issues.

Taxes and social security charges	2024	2023
VAT NL	108.173	126.844
VAT IT	(12.536)	116.984
VAT GER	-	19.941
VAT Spain	2.100	(85.944)
<b>Total Taxes and social security charges</b>	<b>97.737</b>	<b>177.826</b>

Other receivables, prepayment and accrued income.	2024	2023
EHA2025	1.279.602	
TRTH, CRTH, CBTH	391.442	360.583
General	206.964	342.808
7th CAR T meeting 2025	152.576	
Recon	89.143	
Rent/Office Management	64.831	58.872
IT	42.034	
Tutorial Hong Kong (2025)	30.393	
SWGs	20.049	
La Cantera	20.000	
HemaSphere	15.000	99.021
National Societies	12.996	
Harmony		224.150

<b>Total Receivables, prepayments, accrued income</b>	<b>2.325.031</b>	<b>1.085.434</b>
---	------------------	------------------

Per 2024, EHA has also received invoices for pre-payments for the congress for 2025. As these costs belong to 2025. They have been booked on the suspense account.

<b>Cash and cash equivalents</b>	<b>2024</b>	<b>2023</b>
General account	25.767.480	23.899.949
Foreign currency account	105.954	226.955
Guarantees and Deposits	4.090.821	7.090.821
PayPal	125.800	116.212
<b>Total cash and cash equivalents</b>	<b>30.090.055</b>	<b>31.333.937</b>

Guarantees sum up to EUR 90.821. Deposit account is accessible per 6 months, but has a higher interest rate than our general account. There is EUR 4mln on our deposit account.

Due to an administrative issues EHA did not have access to its PayPal account. During the course of 2025, this issue will be resolved.

#### Specification of Equity and Liabilities

<b>Other reserves</b>	<b>2024</b>	<b>2023</b>
Balance start year	27.211.175	25.913.552
Allocation of year result 2024	(4.391.598)	1.297.623
<b>Other reserve balance per end year</b>	<b>22.819.577</b>	<b>27.211.175</b>

<b>EHA fund reserve</b>	<b>2024</b>	<b>2023</b>
Balance start year	1.500.000	-
Allocation to the fund	-	1.500.000
Withdrawal from the fund	(500.000)	
<b>EHA Fund balance per end year</b>	<b>1.000.000</b>	<b>1.500.000</b>

In 2023, €1.5 mln was allocated from our gross result to the special fund reserve (EHA Fund). In 2024, the payout of €500k was corrected via net result in a withdrawal from this fund.

<b>Taxes and social security</b>	<b>2024</b>	<b>2023</b>
Taxes and social security	116.352	114.470

Consists of payable wage tax for the month of December 2024

<b>Other liabilities, accruals and deferred income</b>	<b>2024</b>	<b>2023</b>
Deferred income sponsorships	1.583.280	495.000
Deferred income Ascertain	204.729	204.729

Deferred income 7th CAR T meeting 2025	208.946	
Deferred income EHA congress	566.000	1.288.815
Accrued costs	39.786	
EHA friend fund	24.141	24.141
Holiday Allowance	168.422	143.344
Accrued holiday	149.606	121.547
Other liabilities		260.085
Accounting expenses	30.000	25.000
Education		338.449
<b>Balance per end year</b>	<b>2.974.910</b>	<b>2.901.110</b>

### **Contingent assets and liabilities**

#### **Rental commitment building**

The European Hematology Association has a long-term rental commitment until 2032, which relates to the rent of the office. The quarterly amount is EUR 56.791 (incl. rent discounts, excl. service charges). This amounts to 1.817mln at the end of the contract.

#### **Off balance sheet obligations**

The European Hematology Association (EHA) has been actively participating in the T2EVOLVE initiative since its launch in 2021. This five-year project operates under the European Union's Innovative Medicines Initiative (IMI). Throughout its duration, EHA has set the intention to an annual investment of €200,000, with the initiative set to conclude in 2025.

## Notes to the statement of income

### Specification of profit per cost center

Connect	Actual 2024	Budget 2024	Actual 2023
EHA congress	19.087.682	16.375.800	17.490.947
Other meetings	514.140	464.000	200.909
<b>Revenue Congress &amp; meeting</b>	<b>19.601.822</b>	<b>16.839.800</b>	<b>17.691.856</b>

With 18,709 attendees and enhanced sponsorship opportunities, the 2024 EHA Congress marked its most successful edition to date.

Public Relations	Actual 2024	Budget 2024	Actual 2023
Corporate Sponsorships	3.519.714	4.000.000	4.239.291
General	5.000		
<b>Revenue Public Relations</b>	<b>3.524.714</b>	<b>4.000.000</b>	<b>4.239.291</b>

Community	Actual 2024	Budget 2024	Actual 2023
Membership	702.993	709.000	600.642
EBAH	76.285		
General	15.064		
<b>Revenue Engagement</b>	<b>794.342</b>	<b>709.000</b>	<b>600.642</b>

EHA membership increased with 1.013 to a total of 7.877 members. The average fee per member increased from € 79,- in 2023 to € 89,- 2024.

Research	Actual 2024	Budget 2024	Actual 2023
GoCART Passport Project	287.500		
CBTH, CRTH, TRTH	95.000	190.000	-
General	830		25.320
Harmony	130.469		298.217
Supply			54.862
<b>Revenue Research</b>	<b>513.799</b>	<b>190.000</b>	<b>378.399</b>

The Research department exceeded budget due to the success of the unbudgeted GoCART passport project and final payment of the Harmony project. Meanwhile, the CBTH/CRTH projects fell short as sponsors had misalignment with EHA regarding priorities.

Education	Actual 2024	Budget 2024	Actual 2023
-----------	-------------	-------------	-------------

General	120.873,17	615.000	41.966
Lighting the flame	220.811,22	150.000	115.382
Sponsorships	75.000,00		289.179
<b>Revenue Education</b>	<b>416.684</b>	<b>765.000</b>	<b>446.527</b>

The education department fell short of its budgeted profit due to Project CPP. EHA remain confident in its potential, but has yet to secure support from the pharmaceutical industry.

Scientific Publications	Actual 2024	Budget 2024	Actual 2023
HemaSphere	85.000	465.000	189.610
<b>Revenue Scientific Publications</b>	<b>85.000</b>	<b>465.000</b>	<b>189.610</b>

The Scientific Publications department fell short of its budgeted revenue in 2024 due to a publisher transition. The new publisher operates under a different compensation model, with revenue expected to materialize in 2025.

<b>Miscellaneous</b>		<b>7.100</b>	
<b>Total Revenue EHA</b>	<b>24.936.362</b>	<b>22.975.900</b>	<b>23.546.325</b>



## Notes to the statement of expense

### Specification of costs per cost center

Connect	Actual 2024	Budget 2024	Actual 2023
EHA congress	9.614.387	8.427.000	7.957.888
Operational costs	659.175	729.000	
other meetings	312.142	879.000	2.403.248
Tutorials	83.245		
CAR T meetings	39.387		
<b>Total</b>	<b>10.708.335</b>	<b>10.035.000</b>	<b>10.361.136</b>

Research	Actual 2024	Budget 2024	Actual 2023
Grants	4.814.238	3.950.000	2.854.229
Operational costs	924.417	660.000	699.289
TRTH	292.539	170.000	
CRTH	212.258	205.000	
CBTH	204.221	180.000	
T2Evolve	133.634	326.000	77.276
GoCart	81.762		71.842
Harmony	404.012	130.000	260.618
other costs	25.524		35.000
<b>Total</b>	<b>7.092.604</b>	<b>5.621.000</b>	<b>3.998.254</b>

The increase in grant expenses by €884,000 was not initially accounted for in the 2024 budget. However, additional funds were allocated due to the submission of high-quality grant proposals.

Education	Actual 2024	Budget 2024	Actual 2023
Operational costs	1.284.373	808.000	950.501
Online	337.840	600.000	148.821
Lighting the Flame	113.653	235.000	
Tutorials	83.493	205.000	
Grants	139.505		
other costs	14.460	176.000	
<b>Total</b>	<b>1.973.324</b>	<b>2.024.000</b>	<b>1.099.322</b>

Engagement	Actual 2024	Budget 2024	Actual 2023
Operational costs	1.356.992	718.000	737.212

Grants	901.682	600.000	
SWG	285.261	719.000	
other meetings/costs	233.629	323.000	162.338
Topic in focus	163.388		
National Societies	25.674	368.000	58.020
EBAH	24.054		
Young EHA	9.231	42.000	
<b>Total</b>	<b>2.999.911</b>	<b>2.770.000</b>	<b>957.570</b>

Public Relations	Actual 2024	Budget 2024	Actual 2023
Operational costs	1.677.699	1.530.000	392.184
EHA congress	34.273		
<b>Total</b>	<b>1.711.972</b>	<b>1.530.000</b>	<b>392.540</b>

Public relations costs rose due to EHA's new branding with expenses incurred in 2024.

Scientific Publications	Actual 2024	Budget 2024	Actual 2023
Operational costs	548.733	1.311.000	59.303
HemaSphere	244.889		275.063
EHA guidelines	86.709		
<b>Total</b>	<b>880.331</b>	<b>1.311.000</b>	<b>334.365</b>

European Affairs	Actual 2024	Budget 2024	Actual 2023
Operational costs	500.601	447.000	371.110
Grants	150.323	100.000	
Reducing Bureaucracy	168.092	76.000	
Other projects	1.914	231.000	8.156
Supply	80.699	12.000	107.643
<b>Total</b>	<b>901.630</b>	<b>866.000</b>	<b>486.910</b>

Internal departments	Actual 2024	Budget 2024	Actual 2023
Operations, Board and People	3.780.408	2.994.000	3.092.363
Good Governance	37.338	30.000	30.272
Works Council	8.949	20.000	
<b>Total</b>	<b>3.826.695</b>	<b>3.044.000</b>	<b>3.122.635</b>

The Operations department's costs increased due to a one-time payment covering an office revamp, a donation to a hospital in Ukraine, and the resolution of Project Harmony.

<b>Total Costs EHA</b>	<b>30.094.802</b>	<b>27.201.000</b>	<b>20.752.732</b>
------------------------	-------------------	-------------------	-------------------

### Specification EHA wages and salaries

At the European Hematology Association (EHA), each department manages its own wages and salary expenses, which are incorporated into the respective department's operational costs. Below is a breakdown of the total wages and salary expenses at the organizational level.

	<b>Actual 2024</b>	<b>Actual 2023</b>
Salaries	3.558.398	2.949.510
Wage tax	584.933	507.595
Pensions	611.599	494.510
other employment costs	141.251	49.293
<b>Total</b>	<b>4.896.181</b>	<b>4.000.909</b>
Wage costs increased in line with growth in FTE and inflation correction.		

### Budget 2025

Drawing from EHA's strategic framework, valuable insights were gathered from the organization's Committees and Working Groups to shape the 2025 Work Plan and Budget.

Input was provided at two levels:

- EHA's existing program portfolio and proposed strategic direction in 2025
- New EHA program initiatives fitting within the EHA's overarching strategy.

For ongoing projects as well as for new program initiatives, the scopes of these initiatives were developed, including the budgets, and collected in a draft Work and Budget 2025, which was approved by the Board.

<b>Department</b>	<b>Income</b>
Connect	18.813.228
Education	660.000
Engagement	2.310.000
Public Relations	4.300.000
Research	120.000
Scientific Publications	515.579
<b>Total</b>	<b>26.718.807</b>

Department	Expenses
Board	238.260
Connect	12.194.667
Education	2.303.564
Engagement	2.166.284
European Affairs	883.225
Good Governance	32.300
Operations	2.372.755
Public Relations	1.254.642
Research	6.655.805
Scientific Publications	1.400.839
Works Council	10.000
<b>Total</b>	<b>29.512.340</b>

<b>Gross result</b>	<b>(2.793.533)</b>
<b>Financial result</b>	<b>309.225</b>
<b>Net result</b>	<b>(2.484.308)</b>

## Investing in the Future

At the November meeting, the EHA Board also discussed its ambition to grow and expand activities in Knowledge, Congress & Meetings, and Engagement to ensure that EHA broadens its current benefits for members and non-members and can fulfill and broaden its strategic goals. EHA's financial position is solid, allowing the association to develop and implement valuable programs that contribute to achieving its strategic goals. New programs have been presented to the EHA Board to obtain approval for an additional investment plan for 2025 and beyond.